As mentioned earlier, the expression levels of both TFE3 and TP53 were upregulated in CRSwNP, thus the drugs that could make the biomarkers downregulated were selected as potential therapeutic agents for CRSwNP. This evidence concerns the gene TP53 and chronic rhinosinusitis with nasal polyps.